NCRC Featured Stories

November 09, 2012

Mark S. Cohen MD, FACS, Associate Professor of Surgery and Director of Endocrine Surgery Research recently moved his lab to NCRC from the University of Kansas, as part of the Translational Oncology program. We spoke with him recently.

About his research and his move to NCRC We are very excited to move in here at NCRC. As a clinician/scientist, I try to bridge my translational cancer research into clinical applications for patients with endocrine tumors, head and neck cancer, breast cancer, and melanoma. My clinical efforts are focused on cancer patients with...

November 09, 2012

The University of Michigan Health System has earned a $9.1 million core grant from the National Institutes of Health to improve disease diagnosis through metabolic profiling.

With the support, the U-M will create the Michigan Regional Comprehensive Metabolomics Research Core, one of only three centers in the country that will help researchers examine small molecules called metabolites to detect changes in cell behavior and organ function.

The sum of all metabolites at any given moment — the metabolome — is a form of chemical readout of the state of health of the cell or...

June 25, 2012

First researchers move to new home of U-M’s Institute for Healthcare Policy and Innovation at North Campus Research Complex

With a common goal of making health care better, safer, more cost effective and more equal, nearly 400 health researchers from across the University of Michigan and partner organizations have formed one of the nation’s largest research entities of its kind.

The Institute for Healthcare Policy and Innovation, which opened its new home just days ago, unites members of an already strong health care research community in a new way – making U-M a true...

January 20, 2012

Lycera Corp. settles into new space as public-private partner at complex

ANN ARBOR, Mich. — With a new leader and new labs at the North Campus Research Complex, Lycera Corp. has the space it needs to continue to unravel the challenge of treating autoimmune diseases.

Lycera, founded by a U-M professor, pioneers innovative approaches to the discovery and development of novel oral medicines for treating autoimmune diseases like rheumatoid arthritis and lupus.

The company moved into 14,000 square feet at NCRC this fall, bringing 25 employees, including a new chief...

January 12, 2012

New medical school department finds home at NCRC

In the fast-changing world of medical research, computational medicine and bioinformatics is an emerging field in which scientists are asking how they can use the scalability of computers, computational methods, and the growing tsunami of heterogeneous data and information resources to develop general biological and biomedical solutions applicable to a variety of specific problems.

U-M has an already established and successful Center for Computational Medicine and Bioinformatics (CCMB), a campus-wide interdisciplinary...

October 13, 2011

You are hereHome › NCRC by the Numbers NCRC BY THE NUMBERS An Update on the North Campus Research Complex

In 2009, when the University purchased the former Pfizer complex near North Campus and established the North Campus Research Complex, the vision was to create “a world of fast-paced scientific discovery that ignites improvements to human­ity’s health and well-being.”

At the time, it was hard to predict how quickly that vision might take flight. Just two years later, that vision is rapidly becoming a reality.

ncrc growth diagramThis diagram represents the areas...

August 31, 2011

U-M launched its Venture Accelerator, part of U-M Tech Transfer, at the NCRC with an open house and ribbon-cutting ceremony in January 2011. Occupying 18,000 square feet at the NCRC, the Venture Accelerator focuses exclusively on enhancing the quality and speed of developing high-potential new ventures based on U-M technology. Accelerator tenants have access to Tech Transfer's Venture Center to help them refine business models, attract investors, acquire gap funding and connect to talent who enhance the company's quality and sustainability. Accelerator tenants can also seek guidance from...

August 11, 2011

Imagine having a serious illness that will respond to drugs specifically tailored to you – taking into account your genetic makeup, your drug tolerance, even your other illnesses. This is an example of “personalized medicine,” and research being conducted at the University of Michigan is bringing this next step in healthcare closer to actual patients every day.

Jay L. Hess, M.D., Carl Vernon Weller Professor and Chair of Pathology, who is heading up the UMHS deployment team in personalized medicine, describes personalized medicine as providing “The right treatment, for the right...

August 03, 2011

“A dozen leading pharmaceutical companies are now pursuing work we pioneered,” says Haile Tecle, Ph.D., “but nobody would touch this in the beginning.”

Tecle is referring to the successful MEK kinase inhibitor cancer research he and Judith Sebolt-Leopold and their team have conducted since the 1990s when they both worked at Pfizer Pharmaceutical Research in Ann Arbor, Michigan.

Now their former Pfizer facility is the University of Michigan North Campus Research Complex, purchased by U-M in 2009 after Pfizer left town – and a testbed for translational and interdisciplinary...